NO20044767L - Farmasoytisk formulering med modifisert frigjoring - Google Patents
Farmasoytisk formulering med modifisert frigjoringInfo
- Publication number
- NO20044767L NO20044767L NO20044767A NO20044767A NO20044767L NO 20044767 L NO20044767 L NO 20044767L NO 20044767 A NO20044767 A NO 20044767A NO 20044767 A NO20044767 A NO 20044767A NO 20044767 L NO20044767 L NO 20044767L
- Authority
- NO
- Norway
- Prior art keywords
- modified release
- pharmaceutical formulation
- compound
- formula
- pharmaceutically acceptable
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/397—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having four-membered rings, e.g. azetidine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
- A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P39/00—General protective or antinoxious agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P41/00—Drugs used in surgical methods, e.g. surgery adjuvants for preventing adhesion or for vitreum substitution
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/10—Antioedematous agents; Diuretics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
Landscapes
- Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Epidemiology (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Neurosurgery (AREA)
- Biomedical Technology (AREA)
- Hematology (AREA)
- Neurology (AREA)
- Hospice & Palliative Care (AREA)
- Diabetes (AREA)
- Toxicology (AREA)
- Oncology (AREA)
- Communicable Diseases (AREA)
- Surgery (AREA)
- Urology & Nephrology (AREA)
- Psychiatry (AREA)
- Pain & Pain Management (AREA)
- Rheumatology (AREA)
- Vascular Medicine (AREA)
- Pulmonology (AREA)
- Medicinal Preparation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
SE0201659A SE0201659D0 (sv) | 2002-05-31 | 2002-05-31 | Modified release pharmaceutical formulation |
PCT/SE2003/000858 WO2003101424A1 (en) | 2002-05-31 | 2003-05-27 | Modified release pharmaceutical formulation |
Publications (1)
Publication Number | Publication Date |
---|---|
NO20044767L true NO20044767L (no) | 2005-02-25 |
Family
ID=20288037
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
NO20044767A NO20044767L (no) | 2002-05-31 | 2004-11-03 | Farmasoytisk formulering med modifisert frigjoring |
Country Status (23)
Country | Link |
---|---|
US (1) | US7202236B2 (pt) |
EP (1) | EP1513495A1 (pt) |
JP (2) | JP4603353B2 (pt) |
KR (1) | KR101166921B1 (pt) |
CN (2) | CN101264051B (pt) |
AR (1) | AR039936A1 (pt) |
AU (2) | AU2003232870B2 (pt) |
BR (1) | BR0311460A (pt) |
CA (1) | CA2485535C (pt) |
EG (1) | EG24479A (pt) |
IL (1) | IL165029A0 (pt) |
IS (1) | IS7564A (pt) |
MX (1) | MXPA04011914A (pt) |
NO (1) | NO20044767L (pt) |
NZ (1) | NZ536621A (pt) |
PL (1) | PL374299A1 (pt) |
RU (2) | RU2352323C2 (pt) |
SA (1) | SA03240402B1 (pt) |
SE (1) | SE0201659D0 (pt) |
SG (1) | SG165162A1 (pt) |
TW (2) | TWI319317B (pt) |
WO (1) | WO2003101424A1 (pt) |
ZA (1) | ZA200409234B (pt) |
Families Citing this family (25)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
AR035216A1 (es) * | 2000-12-01 | 2004-05-05 | Astrazeneca Ab | Derivados de acido mandelico ,derivados farmaceuticamente aceptables, uso de estos derivados para la fabricacion de medicamentos, metodos de tratamiento ,procesos para la preparacion de estos derivados, y compuestos intermediarios |
AR034517A1 (es) | 2001-06-21 | 2004-02-25 | Astrazeneca Ab | Formulacion farmaceutica |
SE0201658D0 (sv) * | 2002-05-31 | 2002-05-31 | Astrazeneca Ab | Immediate release pharmaceutical formulation |
SE0201661D0 (sv) * | 2002-05-31 | 2002-05-31 | Astrazeneca Ab | New salts |
US7781424B2 (en) * | 2003-05-27 | 2010-08-24 | Astrazeneca Ab | Modified release pharmaceutical formulation |
EP1849004A1 (en) | 2005-01-17 | 2007-10-31 | Gyros Patent Ab | A versatile flow path |
TW200827336A (en) | 2006-12-06 | 2008-07-01 | Astrazeneca Ab | New crystalline forms |
TW200900033A (en) * | 2007-06-21 | 2009-01-01 | Wen-Qing Li | Automatic brewing machine |
US20080317790A1 (en) * | 2007-06-25 | 2008-12-25 | Cp Kelco U.S., Inc. | Process for Treatment of Kappa Carrageenan |
US8268808B2 (en) * | 2007-06-25 | 2012-09-18 | Cp Kelco U.S., Inc. | Carrageenan and carrageenan-containing products |
EP2181116A4 (en) * | 2007-06-25 | 2013-02-27 | Cp Kelco Us Inc | CARRAGEENAN |
US20080317791A1 (en) * | 2007-06-25 | 2008-12-25 | Cp Kelco U.S., Inc. | Kappa Carrageenan |
US20080317926A1 (en) * | 2007-06-25 | 2008-12-25 | Cp Kelco U.S., Inc. | Carrageenan Process |
US20080317789A1 (en) * | 2007-06-25 | 2008-12-25 | Cp Kelco U.S., Inc. | Carrageenan Process |
US20080317927A1 (en) * | 2007-06-25 | 2008-12-25 | Cp Kelco U.S., Inc. | Process for Treatment of Kappa Carrageenan |
US20090061000A1 (en) * | 2007-08-31 | 2009-03-05 | Astrazeneca Ab | Pharmaceutical formulation use 030 |
US9125434B2 (en) * | 2007-10-11 | 2015-09-08 | Philip Morris Products S.A. | Smokeless tobacco product, smokeless tobacco product in the form of a sheet, extrudable tobacco composition, method for manufacturing a smokeless tobacco product, method for delivering super bioavailable nicotine contained in tobacco to a user, and packaged smokeless tobacco product sheet |
US20090098192A1 (en) * | 2007-10-11 | 2009-04-16 | Fuisz Richard C | Extrudable and Extruded Compositions for Delivery of Bioactive Agents, Method of Making Same and Method of Using Same |
EA021392B1 (ru) | 2007-10-11 | 2015-06-30 | Филип Моррис Продактс С.А. | Бездымный табачный продукт |
US20100310522A1 (en) * | 2007-11-26 | 2010-12-09 | Plant Bioscience Limited | Novel Polypeptides Having Endolysin Activity and Uses Thereof |
US8293285B2 (en) * | 2008-03-14 | 2012-10-23 | Cp Kelco U.S., Inc. | Carrageenan modified by ion-exchange process |
US20100159001A1 (en) * | 2008-12-19 | 2010-06-24 | Cardinal John R | Extended-Release Pharmaceutical Formulations |
US20100160363A1 (en) * | 2008-12-19 | 2010-06-24 | Aaipharma Services Corp. | Extended-release pharmaceutical formulations |
GB0908949D0 (en) | 2009-05-26 | 2009-07-01 | Plant Bioscience Ltd | Novel polypeptides having endolysin activity and uses thereof |
CA3036307A1 (en) * | 2016-09-15 | 2018-03-22 | Camurus Ab | Prostacyclin analogue formulations |
Family Cites Families (65)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
HU178398B (en) | 1979-06-12 | 1982-04-28 | Gyogyszerkutato Intezet | Process for producing new agmatine derivatives of activity against haemagglutination |
JPS57149217A (en) | 1981-03-11 | 1982-09-14 | Kaken Pharmaceut Co Ltd | Slow-releasing pharmaceutical preparation |
HU192646B (en) | 1984-12-21 | 1987-06-29 | Gyogyszerkutato Intezet | Process for preparing new n-alkyl-peptide aldehydes |
CA1341029C (en) | 1985-02-04 | 2000-06-20 | Michael Kolb | Peptidase inhibitors |
US5187157A (en) | 1987-06-05 | 1993-02-16 | Du Pont Merck Pharmaceutical Company | Peptide boronic acid inhibitors of trypsin-like proteases |
US4792452A (en) | 1987-07-28 | 1988-12-20 | E. R. Squibb & Sons, Inc. | Controlled release formulation |
EP0362002B1 (en) | 1988-09-01 | 1995-07-26 | Merrell Dow Pharmaceuticals Inc. | HIV protease inhibitors |
ZA897515B (en) | 1988-10-07 | 1990-06-27 | Merrell Dow Pharma | Novel peptidase inhibitors |
TW201303B (pt) | 1990-07-05 | 1993-03-01 | Hoffmann La Roche | |
CA2075154A1 (en) | 1991-08-06 | 1993-02-07 | Neelakantan Balasubramanian | Peptide aldehydes as antithrombotic agents |
SE9102462D0 (sv) | 1991-08-28 | 1991-08-28 | Astra Ab | New isosteric peptides |
US5169638A (en) | 1991-10-23 | 1992-12-08 | E. R. Squibb & Sons, Inc. | Buoyant controlled release powder formulation |
ZA928581B (en) | 1991-11-12 | 1994-05-06 | Lilly Co Eli | Antithrombotic agents |
SE9103612D0 (sv) | 1991-12-04 | 1991-12-04 | Astra Ab | New peptide derivatives |
ES2110599T3 (es) | 1992-03-04 | 1998-02-16 | Gyogyszerkutato Intezet | Nuevos derivados de peptidos anticoagulantes y composiciones farmaceuticas que contienen los mismos, asi como un proceso para su preparacion. |
TW223629B (pt) | 1992-03-06 | 1994-05-11 | Hoffmann La Roche | |
US6984627B1 (en) | 1993-06-03 | 2006-01-10 | Astrazeneca Ab | Peptide derivatives |
SE9301912D0 (sv) | 1993-06-03 | 1993-06-03 | Ab Astra | Process for the production of aminoalkylguandines |
US5783563A (en) | 1993-06-03 | 1998-07-21 | Astra Aktiebolag | Method for treatment or prophylaxis of venous thrombosis |
SE9301916D0 (sv) | 1993-06-03 | 1993-06-03 | Ab Astra | New peptides derivatives |
EP0648780A1 (en) | 1993-08-26 | 1995-04-19 | Bristol-Myers Squibb Company | Heterocyclic thrombin inhibitors |
TW394760B (en) | 1993-09-07 | 2000-06-21 | Hoffmann La Roche | Novel Carboxamides, process for their preparation and pharmaceutical composition containing the same |
AU1025795A (en) | 1994-01-27 | 1995-08-03 | Mitsubishi Chemical Corporation | Prolineamide derivatives |
US5705487A (en) | 1994-03-04 | 1998-01-06 | Eli Lilly And Company | Antithrombotic agents |
ZA951617B (en) | 1994-03-04 | 1997-02-27 | Lilly Co Eli | Antithrombotic agents. |
US5707966A (en) | 1994-03-04 | 1998-01-13 | Eli Lilly And Company | Antithrombotic agents |
US5561146A (en) | 1994-06-10 | 1996-10-01 | Bristol-Myers Squibb Company | Modified guanidino and amidino thrombin inhibitors |
DE4421052A1 (de) | 1994-06-17 | 1995-12-21 | Basf Ag | Neue Thrombininhibitoren, ihre Herstellung und Verwendung |
US5498724A (en) | 1994-06-28 | 1996-03-12 | Aktiebolaget Astra | Pyrazoleamidine compounds |
US5510369A (en) | 1994-07-22 | 1996-04-23 | Merck & Co., Inc. | Pyrrolidine thrombin inhibitors |
CN1198839C (zh) | 1995-02-17 | 2005-04-27 | 艾伯特有限及两合公司 | 作为凝血酶抑制剂的新的二肽脒类 |
US5710130A (en) | 1995-02-27 | 1998-01-20 | Eli Lilly And Company | Antithrombotic agents |
US5695781A (en) | 1995-03-01 | 1997-12-09 | Hallmark Pharmaceuticals, Inc. | Sustained release formulation containing three different types of polymers |
US6083532A (en) | 1995-03-01 | 2000-07-04 | Duramed Pharmaceuticals, Inc. | Sustained release formulation containing three different types of polymers and tablet formed therefrom |
JPH11503161A (ja) | 1995-04-04 | 1999-03-23 | メルク エンド カンパニー インコーポレーテッド | トロンビン阻害剤 |
US5629324A (en) | 1995-04-10 | 1997-05-13 | Merck & Co., Inc. | Thrombin inhibitors |
SA96170106A (ar) * | 1995-07-06 | 2005-12-03 | أسترا أكتيبولاج | مشتقات حامض أميني جديدة |
TW541316B (en) | 1995-12-21 | 2003-07-11 | Astrazeneca Ab | Prodrugs of thrombin inhibitors |
SE9601556D0 (sv) * | 1996-04-24 | 1996-04-24 | Astra Ab | New pharmaceutical formulation of a thrombin inhibitor for parenteral use |
SE9602263D0 (sv) | 1996-06-07 | 1996-06-07 | Astra Ab | New amino acid derivatives |
US5863929A (en) | 1996-06-25 | 1999-01-26 | Eli Lilly And Company | Anticoagulant agents |
SE9602646D0 (sv) | 1996-07-04 | 1996-07-04 | Astra Ab | Pharmaceutically-useful compounds |
DE19632772A1 (de) | 1996-08-14 | 1998-02-19 | Basf Ag | Neue Benzamidine |
SE9603724D0 (sv) * | 1996-10-11 | 1996-10-11 | Astra Ab | New pharmaceutical parenteral formulation of a thrombin inhibitor |
AR013084A1 (es) | 1997-06-19 | 2000-12-13 | Astrazeneca Ab | Derivados de amidino utiles como inhibidores de la trombina, composicion farmaceutica, utilizacion de dichos compuestos para la preparacion demedicamentos y proceso para la preparacion de los compuestos mencionados |
IT1297461B1 (it) | 1997-10-29 | 1999-12-17 | Ciocca Maurizio | Preparazione di compresse a rilascio controllato a base di complessi tra carragenano e farmaci basici solubili |
SE9704543D0 (sv) | 1997-12-05 | 1997-12-05 | Astra Ab | New compounds |
US6251430B1 (en) | 1998-02-04 | 2001-06-26 | Guohua Zhang | Water insoluble polymer based sustained release formulation |
SE9802938D0 (sv) | 1998-09-01 | 1998-09-01 | Astra Ab | Improved stability for injection solutions |
SE9802974D0 (sv) | 1998-09-03 | 1998-09-03 | Astra Ab | New crystalline forms |
SE9802973D0 (sv) | 1998-09-03 | 1998-09-03 | Astra Ab | Immediate release tablet |
WO2000013710A2 (en) | 1998-09-04 | 2000-03-16 | Scios Inc. | Hydrogel compositions for the controlled release administration of growth factors |
SE9804313D0 (sv) | 1998-12-14 | 1998-12-14 | Astra Ab | New compounds |
ES2295004T3 (es) | 1999-01-13 | 2008-04-16 | Astrazeneca Ab | Nuevos derivados amidinobencilaminicos y su uso como inhibidores de trombina. |
SE9902550D0 (sv) | 1999-07-02 | 1999-07-02 | Astra Ab | New crystalline forms |
SE0001803D0 (sv) | 2000-05-16 | 2000-05-16 | Astrazeneca Ab | New compounds i |
AU2001280395B2 (en) | 2000-08-16 | 2005-11-24 | Astrazeneca Ab | New amidino derivatives and their use as thrombin inhibitors |
SE0003125D0 (sv) * | 2000-09-05 | 2000-09-05 | Astrazeneca Ab | Modified polymers |
AR035216A1 (es) * | 2000-12-01 | 2004-05-05 | Astrazeneca Ab | Derivados de acido mandelico ,derivados farmaceuticamente aceptables, uso de estos derivados para la fabricacion de medicamentos, metodos de tratamiento ,procesos para la preparacion de estos derivados, y compuestos intermediarios |
SE0102921D0 (sv) | 2001-08-30 | 2001-08-30 | Astrazeneca Ab | Pharmaceutically useful compounds |
US7129233B2 (en) | 2000-12-01 | 2006-10-31 | Astrazeneca Ab | Mandelic acid derivatives and their use as thrombin inhibitors |
AR034517A1 (es) | 2001-06-21 | 2004-02-25 | Astrazeneca Ab | Formulacion farmaceutica |
UA78195C2 (uk) | 2001-08-30 | 2007-03-15 | Astrazeneca Ab | Похідні мигдалевої кислоти та їх застосування як інгібіторів тромбіну, фармацевтична композиція на їх основі |
SE0201661D0 (sv) | 2002-05-31 | 2002-05-31 | Astrazeneca Ab | New salts |
SE0201658D0 (sv) | 2002-05-31 | 2002-05-31 | Astrazeneca Ab | Immediate release pharmaceutical formulation |
-
2002
- 2002-05-31 SE SE0201659A patent/SE0201659D0/xx unknown
-
2003
- 2003-05-27 EP EP03728205A patent/EP1513495A1/en not_active Withdrawn
- 2003-05-27 AU AU2003232870A patent/AU2003232870B2/en not_active Ceased
- 2003-05-27 RU RU2004132856/15A patent/RU2352323C2/ru not_active IP Right Cessation
- 2003-05-27 CN CN200810099130XA patent/CN101264051B/zh not_active Expired - Fee Related
- 2003-05-27 CN CNB038124920A patent/CN100402025C/zh not_active Expired - Fee Related
- 2003-05-27 SG SG200608336-4A patent/SG165162A1/en unknown
- 2003-05-27 KR KR1020047019336A patent/KR101166921B1/ko not_active IP Right Cessation
- 2003-05-27 JP JP2004508782A patent/JP4603353B2/ja not_active Expired - Fee Related
- 2003-05-27 US US10/516,420 patent/US7202236B2/en not_active Expired - Fee Related
- 2003-05-27 BR BR0311460-0A patent/BR0311460A/pt not_active IP Right Cessation
- 2003-05-27 NZ NZ536621A patent/NZ536621A/en not_active IP Right Cessation
- 2003-05-27 WO PCT/SE2003/000858 patent/WO2003101424A1/en active Application Filing
- 2003-05-27 RU RU2008142261/15A patent/RU2474416C2/ru not_active IP Right Cessation
- 2003-05-27 MX MXPA04011914A patent/MXPA04011914A/es active IP Right Grant
- 2003-05-27 PL PL03374299A patent/PL374299A1/xx unknown
- 2003-05-27 CA CA2485535A patent/CA2485535C/en not_active Expired - Fee Related
- 2003-05-30 TW TW092114767A patent/TWI319317B/zh not_active IP Right Cessation
- 2003-05-30 AR ARP030101934A patent/AR039936A1/es not_active Application Discontinuation
- 2003-05-30 TW TW097139255A patent/TWI319318B/zh not_active IP Right Cessation
- 2003-11-22 EG EG2003111045A patent/EG24479A/xx active
- 2003-11-30 SA SA3240402A patent/SA03240402B1/ar unknown
-
2004
- 2004-11-03 NO NO20044767A patent/NO20044767L/no not_active Application Discontinuation
- 2004-11-04 IL IL16502904A patent/IL165029A0/xx unknown
- 2004-11-17 ZA ZA200409234A patent/ZA200409234B/en unknown
- 2004-11-29 IS IS7564A patent/IS7564A/is unknown
-
2009
- 2009-08-06 JP JP2009183614A patent/JP2009298795A/ja active Pending
- 2009-12-04 AU AU2009243524A patent/AU2009243524A1/en not_active Abandoned
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
NO20044767L (no) | Farmasoytisk formulering med modifisert frigjoring | |
SE0202463D0 (sv) | Novel compounds | |
HK1080470A1 (en) | Heterocyclic compounds | |
NO20025821L (no) | 2-aminokarbonyl-9H-purinderivater | |
NO20062292L (no) | Fremgangsmate for behandling av transplantasjonsavstoting | |
CA2478374A1 (en) | N3 alkylated benzimidazole derivatives as mek inhibitors | |
HK1079522A1 (en) | Thienyl compounds | |
NO20054852L (no) | GFAT inhibitorer | |
DK1406876T3 (da) | 2-anilinopyrimidinderivater som inhibitorer af cyclinafhængige kinaser | |
DE60334536D1 (de) | Furylverbindungen | |
NO20054787D0 (no) | Indenderivater som farmasotiske midler | |
NO20050667L (no) | N-substituerte-1H-indol-5-propionsyreforbindelser som PPAR agonister nyttige for behandling av diabetes | |
SE0302573D0 (sv) | Benzimidazole derivatives, compositions containing them, preparation thereof and uses thereof | |
SE0104250D0 (sv) | Heterocyclic compounds | |
SE0300908D0 (sv) | Azaindole derivatives, preparations thereof, uses thereof and compositions containing them | |
NO20044810L (no) | Farmasoytisk formulering med oyeblikkelig frigjoring | |
SE0302756D0 (sv) | Novel Compounds | |
MXPA05013050A (es) | Derivados de bencimidazol, composiciones que los contienen preparacion de los mismos y usos de los mismos. | |
SE0302570D0 (sv) | Benzimidazole derivatives, compositions containing them, preparation thereof and uses thereof | |
AU5705099A (en) | Compounds useful as aicarft inhibitors | |
SE0203302D0 (sv) | Novel Compounds | |
SE0302572D0 (sv) | Benzimidazole derivatives, compositions containing them, preparation thereof and uses thereof | |
SE0300105D0 (sv) | Diarylmethylidene piperdine derivatives, preparations thereof and uses thereof | |
MXPA04009421A (es) | Compuestos de tiazol-2-ilimina como inhibidores de la pde-7. | |
NO20041671L (no) | Anthelmintic composition |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
FC2A | Withdrawal, rejection or dismissal of laid open patent application |